Please note changes have been made to the order of speakers

To Register for the 15th International Symposium on Translational Research in Oncology please click here

For printable version of programme please click here: Final Programme – 15th International Symposium on Translational Research in Oncology


Wednesday, 28th September 2022, Lansdowne Suite

09.00 – 12.30 AICRI Showcase To register for the AICRI showcase click here

Registration for symposium from 12:30                                CPD: 3 external points

13:30 – 13.45 Welcome and Introduction – Prof John Crown, St. Vincent’s University Hospital, Dublin

TARGETED THERAPIES IN CANCER I: Session Chair – Prof. Sara Hurvitz, UCLA

13:45 – 14:15 Identifying Novel Targets and Targeted Therapies for Breast Cancer

Prof. Sara Hurvitz, Professor of Medicine and Director, Breast Cancer Clinical Trials Program, Division of Hematology/Oncology, David Geffen School of Medicine, UCLA. Medical Director, Clinical Research Unit, Jonsson Comprehensive Cancer Center.

14:15 – 14:45 Therapeutic Application of ADCs: Challenging the Current Breast Cancer Classification

Dr. Aditya Bardia, Director, Breast Cancer Research, Medical Oncology, Massachusetts General Hospital Cancer Center, Associate Professor, Harvard Medical School, Boston

14:45 – 15:15 Beyond ADCs – Next Generation Targeted Therapeutics

Dr. Richard Markus, President and CEO, Dantari

15:15 – 15:30 Coffee break


15:30 – 16:15  Identifying Novel Targets and Targeted Therapies for Cancer

Dr. Dennis J. Slamon, 2019 Lasker Award Winner, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women’s Cancer Research Program at JCCC. Professor of Medicine, Chief, Division of Hematology/Oncology and Executive Vice Chair for Research, Department of Medicine, UCLA.

TARGETED THERAPIES IN CANCER II: Session Chair – Prof. Sara Hurvitz, UCLA

16:15 – 16:45 Development of a Novel Therapeutic mAb and ADC for the Treatment of CLDN18.2-positive Cancers

Dr. Neil O’Brien, Adjunct Associate Professor, Dept of Medicine, Division of Hematology/Oncology, UCLA

16:45 – 17:15 Targeting Acetyl-CoA-carboxylase in breast cancer

Dr. Lajos Pusztai, Professor of Medicine, Yale University and Director of Breast Cancer Translational Research and Co-Director of the Cancer Center Genomics, Genetics, and Epigenetics Program


Thursday, 29th September 2022, Lansdowne Suite, Herbert Park Hotel

Registration from 08:30                                                     CPD: 5 external points

TUMOUR MICRO-ENVIRONMENT I: Session Chair – Prof. Bob Kerbel, University of Toronto

09:00 – 09:30 Preclinical Modelling of Authentic’ Acquired Resistance to Immune Checkpoint Antibody Blockade

Professor Bob Kerbel & Dr. Kabir Khan, Sunnybrook Research Institute University of Toronto

09:30 – 10:00 Effects of Arenaviros-based Immuno-Virotherapy on the Tumor Microenvironment (TME): Inducing Tumor-Destroying Immune Effects

Dr. Thomas Bogenrieder, CMO, Abalos Therapeutics

10:00 – 10:30 Clinical Development of Olinvacimab and PMC-403 and their Scientific Rationale

Dr. Jin-San Yoo, President & CEO, PharmAbcine, Inc

10:30 – 10:45 Coffee break

TUMOUR MICRO-ENVIRONMENT II: Session Chair – Prof. Bob Kerbel, University of Toronto

10:45 – 11:15 The Immunological Host Response to Immunotherapy: Towards Biomarker Discovery and Therapeutic Opportunities.

Prof Yuval Shaked, The Annie Chutick Chair in Medicine, Director, Rappaport-Technion-Integrated Cancer Center, Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology

11.15 – 11:45 Targeting the Metastatic Niche

Prof Janine Erler, Professor in Cancer Biology, Biotech Research and Innovation Centre, University of Copenhagen, Denmark

11:45 – 12:15 Stromal Fibroblasts Sculpt Tumour Evolution and Therapy Responses

Dr. Erik Sahai, Principal Group Leader, Assistant Research Director, The Francis Crick Institute, London


12:15 – 13:00 Development of Novel Ubiquitin System-based Anti Cancer Drugs.

Prof. Aaron Ciechanover, 2004 Nobel Laureate, Distinguished Professor, Technion-Israel Institute of Technology

13:00 – 14:00 Lunch


Session Chair – Prof Michael J. Duffy, St. Vincent’s University Hospital/University College Dublin

14:00 – 14:30 Targeting “Undruggable” Genes: Update 2022

Prof Michael J. Duffy, Clinical Research Centre, St. Vincent’s University Hospital, Dublin.

14:30 – 15:00 Developing a Clinically Viable MYC Inhibitor for Cancer Treatment

Prof Laura Soucek, Group Leader, Vall d’Hebron Institut d’Oncologia, ICREA Research Professor, Spain

15:00 – 15:30 Sotorasib, the First Approved KRAS Inhibitor

John Waldron, Medical Science Liaison (Haematology/Oncology), Amgen Ireland

15:30 – 15:45 Coffee break

IO THERAPIES : Session Chair – Prof John Crown, St. Vincent’s University Hospital

15:45 – 16.15 The Evolution of Neoadjuvant Immunotherapy for Lung Cancer – Translational Science to Clinical Results

Dr. Patrick Forde, Assoc Prof Oncology, Johns Hopkins University, Baltimore

16:15 – 16:45 Advances in CAR T Cell Therapies for Solid Tumors

Prof Roisin O’Cearbhaill, Research Director, Gynecologic Medical Oncology and Clinical Director, Solid Tumor Malignancies, Cellular Therapy Center, Memorial Sloan Kettering Cancer Center, New York.

16:45 – 17:15 Hepatobiliary Cancers: Clinical/ Scientific Advances and Unmet Needs

Dr. Richard Finn, Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, UCLA.


Friday 30th September 2022, Lansdowne Suite, Herbert Park Hotel

Registration from 8:30                                                              CPD: 3 external points

NOVEL TARGETED DRUGS AND BIOMARKERS: Session Chair – Prof William Gallagher, University College Dublin

09:00 – 09:30 Mapping the Degradation Landscape in Cancer Reveals Insight into Anti-Tumor Immunity

Dr. Yifat Merbl, Senior Scientist, Weizmann Institute of Science, Israel

09:30 – 10:00 Clinical validation of conceptually novel anti-hypoxia A2-adenosinergic immunotherapies in cancer patients who were otherwise refractory to all other current treatments

Prof Michail Sitkovsky, E.Black Professor of Immunophysiology and Pharmaceutical Biotechnology, Director, NE Inflammation and Tissue Protection Institute Northeastern University.

10:00 – 10:30 Using the Immune System to Detect Cancer

Prof. Josh LaBaer, Executive Director, Biodesign Institute, Arizona State University

10:30 – 10:45 Coffee break

ANTIBODY DRUG CONJUGATES: Session Chair – Prof John Crown, St. Vincent’s University Hospital

10:45-11:15 Advancing Trop-2 directed ADCs into breast cancer and beyond

Dr. See Phan, VP, Clinical Research Oncology, Gilead Sciences

11:15 – 11:45Development of Antibody-Drug-Conjugates: Current and future outlook

Dr. Rodney Smith, Head of European Medical Affairs Oncology, Daiichi-Sankyo

11:45 – 12:15 Translating the Antitumor Activity of Enfortumab Vedotin to Enable a Novel Option for Patients with NMIBC

Dr. Christopher Carosino, Associate Director Toxicology, PADCEV Translational Sciences Lead, Investigative Toxicology Group Lead

12:15 – 13:15 Lunch

CANCER IMMUNOTHERAPY I: Session Chair – Prof. Mario Sznol, Yale

13:15 – 13:45 The Future of Immunotherapy in Melanoma: LAG-3 and Beyond

Dr. Giuseppe Gullo, Sr. Director, Clinical Sciences, Oncology, Regeneron

13:45 – 14:15 Bench to Bedside Trials in Uveal Melanoma at Sylvester Cancer Center

Dr. Jose Lutzky, Leader, Cutaneous and Ocular Oncology Site Disease Group

Medical Director, Clinical Trials Office, Professor of Clinical Medicine, University of Miami Sylvester Comprehensive Cancer Center.

14:15 – 14:45 Topic: Identifying new targets and how to identify new ImmTAX

Dr. Peter Molloy, Director of Protein Engineering in Research, Immunocore

14:45 – 15:00 Coffee break

CANCER IMMUNOTHERAPY II: Session Chair – Prof. Mario Sznol, Yale

15:00 – 15:30 Anti-CD47 plus Trastuzumab Induces Pacrophage phagocytosis (ADCP) of HER2-positive Breast Cancer Cells selected for Tolerance to Mrastuzumab-mediated ADCC.

Dr. Mark Pegram, Susy Yuan-Huey Hung Prof Med Oncology, Stanford University School of Medicine

15:30 – 16:00 Results of a RCT phase 3, comparing ipilimumab with TIL therapy for advanced stage melanoma having failed anti-PD-1

Prof. Dr. John. B.A.G. Haanen, Medical Oncology Department, Netherlands Cancer Institute

16:00 – 16:30 Designing and delivering next-generation TCR T-cell therapies

Dr. Joanna Brewer, Chief Scientific Officer, Adaptimmune LLC

16:30 – 17:00 Topic: Il-2 ortholog

Dr. Martin Oft, Chief Development Officer, Synthekine

Meeting Ends

Similar Posts